Razoxane, (R)-

• CAT Number: I035454
• CAS Number: 24613-06-7
• Molecular Formula: C11H16N4O4
• Molecular Weight: 268.27
• Purity: 98%
• Synonyms: Razoxane, (R)-; ICRF-186; ICRF 186; ICRF186; NSC-169779; NSC 169779; NSC169779; Levrazoxane
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 4-[(2R)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
• InChI: InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m1/s1
• InChIKey: BMKDZUISNHGIBY-SSDOTTSWSA-N
• SMILES: C[C@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2

(R)-Razoxane(CAT: I035454) is a chiral enantiomer of razoxane, known for its antiangiogenic and antitumor properties. It functions primarily as a topoisomerase II inhibitor, disrupting DNA replication and repair, leading to the inhibition of tumor growth. Additionally, (R)-Razoxane exhibits antiangiogenic effects by reducing vascular endothelial proliferation, thereby suppressing tumor blood supply. This compound has been extensively studied in oncology research for its potential in treating cancers and preventing metastasis. Its dual mechanism of action makes it a valuable tool in understanding tumor biology, angiogenesis, and the development of combination cancer therapies.